Symbols

ABUS

Arbutus Biopharma·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 3

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ABUS

Arbutus Biopharma Corporation

A clinical-stage biopharmaceutical company that developing therapeutics for hepatitis B virus

Industry

Biological Technology

Established Date

10/06/2005

Listing Date

11/15/2010

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.arbutusbio.com

Security Type

Common stock

Office address

701 Veterans Circle , Warminster, PA, 18974

Business

Introduction

Arbutus Biopharma Corporation was incorporated in British Columbia on October 6, 2005. The Company is a clinical-stage biopharmaceutical company that leverages its extensive virology expertise to identify and develop novel therapies with unique mechanisms of action that can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (HBV) infection. The Company's pipeline of proprietary compounds developed in-house includes an RNA therapy drug imdusiran (AB-729) and an oral PD-L1 inhibitor AB-101. Imdusiran has produced meaningful clinical data demonstrating the effects on surface antigen reduction and reawakening of HBV-specific immune responses.

Company Financials

EPS

ABUS has released its 2025 Q3 earnings. EPS was reported at -0.04, versus the expected -0.03568879371875, missing expectations. The chart below visualizes how ABUS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ABUS has released its 2025 Q3 earnings report, with revenue of 529.00K, reflecting a YoY change of -60.49%, and net profit of -7.74M, showing a YoY change of 60.73%. The Sankey diagram below clearly presents ABUS's revenue sources and cost distribution.